Eli Lilly's GLP-1 Drugs Face Potential Coverage Reduction by Employers
Large employers are reconsidering their coverage of Eli Lilly's (LLY) GLP-1 drugs for weight loss, which could impact the company’s revenue. Surveys indicate a potential drop in employer support starting 2027, with some insurers like Cigna already cutting coverage.
Topics: Eli Lilly employer insurance coverage GLP-1 drugs Mounjaro Zepbound